報價延遲最少15分鐘:2026/04/25 19:10 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.31 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.18/-1.02
|
|
企業價值
345.00M
|
| 資產負債 |
|
每股賬面淨值
-1.85
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
30.91M
|
|
每股收益
0.55
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909. |
